Complement C5 inhibition in patients with COVID-19 - a promising target?

Régis Peffault de Latour, Anne Bergeron, Étienne Lengliné, Thibault Dupont, A. Marchal, Lionel Galicier, Nathalie De Castro, Louise Bondeelle, Michaël Darmon, Clairelyne Dupin, Guillaume Dumas, Pierre Leguen, Isabelle Madelaine, Sylvie Chevret, Jean‐Michel Molina, Élie Azoulay, Véronique Frémeaux‐Bacchi, Core GroupHaematologica 2020 · DOI · OpenAlex

This research, published in Haematologica (2020), investigates the role of the complement system—a key component of the innate immune response—in driving the severe inflammatory "cytokine storm" associated with COVID-19. By analyzing plasma biomarkers and conducting a compassionate-use trial of the C5 inhibitor Eculizumab, the study explores whether blocking the terminal complement pathway can mitigate COVID-induced organ damage.

Introduction

Early in the COVID-19 pandemic, clinical observations suggested that severe disease was driven less by direct viral toxicity and more by a dysregulated immune response. This hyper-inflammation often leads to acute respiratory distress syndrome (ARDS) and systemic coagulopathy. The authors hypothesized that the complement system, specifically the formation of the Membrane Attack Complex (MAC or sC5b-9), plays a central role in this pathology by damaging host cells and triggering thrombosis.

Methods and Patient Cohorts

The study analyzed 103 COVID-19 patients admitted to Saint-Louis Hospital in Paris, stratified by disease severity (moderate, severe, and critical) based on oxygen requirements.

Key methodologies included:

  • Biomarker Quantification: Measuring circulating levels of C3, C4, and sC5b-9 via ELISA and nephelometry.
  • Comparative Analysis: Comparing patient data against 68 healthy controls and 40 patients sampled two months post-discharge.
  • Interventional Case Series: Eight high-risk patients with severe pneumonia received Eculizumab, a monoclonal antibody targeting C5, on a compassionate-use basis. Pharmacokinetics were monitored via CH50 levels and free drug concentrations.

Results: Complement Activation and Disease Severity

The study found systemic complement activation in 64% of hospitalized patients. A clear "severity gradient" was observed: sC5b-9 levels correlated directly with clinical worsening. Median sC5b-9 levels in COVID-19 patients were 344 ng/mL, significantly higher than the 160 ng/mL found in healthy controls ($P<0.0001$).

Figure 1: Plasma sC5b-9 levels across healthy controls, COVID-19 severity groups, and post-recovery.

Notably, critical patients exhibited the highest levels of activation. In patients tested two months after discharge, sC5b-9 levels returned to baseline, confirming that the activation was an acute, infection-driven response.

Therapeutic Intervention: Eculizumab Case Series

In the interventional arm, eight patients with severe respiratory failure were treated with Eculizumab. The biochemical response was rapid, with median sC5b-9 levels dropping from 463 ng/mL pre-treatment to 317 ng/mL post-treatment ($P=0.01$).

Figure 3: Clinical and biochemical evolution of eight severe COVID-19 patients treated with Eculizumab.

The "Molecular Sink" Effect

A critical finding was the unique pharmacokinetics of Eculizumab in COVID-19. Patients appeared to "consume" the drug much faster than those with other complement-mediated diseases (like aHUS). This massive activation acts as a "molecular sink," necessitating higher or more frequent dosing (e.g., 1200mg every 4 days) to maintain a complete complement blockade.

Discussion and Clinical Implications

The data suggest a "vicious cycle" where complement activation promotes the formation of Neutrophil Extracellular Traps (NETs), which in turn drive the life-threatening blood clots frequently seen in severe cases.

While the clinical improvement in 6 out of 8 treated patients is promising, the authors acknowledge significant limitations, including the small sample size and the lack of a randomized control group. They conclude that while C5 inhibition is a viable therapeutic target, future clinical trials must account for the high drug clearance rates observed in COVID-19 to ensure efficacy.

Summary updated

BibTeX
@inproceedings{latour2020complement,
  author = {Régis Peffault de Latour and Anne Bergeron and Étienne Lengliné and Thibault Dupont and A. Marchal and Lionel Galicier and Nathalie De Castro and Louise Bondeelle and Michaël Darmon and Clairelyne Dupin and Guillaume Dumas and Pierre Leguen and Isabelle Madelaine and Sylvie Chevret and Jean‐Michel Molina and Élie Azoulay and Véronique Frémeaux‐Bacchi and CORE GROUP},
  title = {{Complement C5 inhibition in patients with COVID-19 - a promising target?}},
  booktitle = {Haematologica},
  year = {2020},
  doi = {10.3324/haematol.2020.260117},
}
Figure